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Abstract
Few studies have shown the correlation between metabolic syndrome and bone mineral density (BMD). The main pathogenic mechanisms of
metabolic syndrome rely on chronic low-level inflammatory status and oxidative stress. There are few studies that examine the gender-specific effects
of inflammation and antioxidants on BMD. In this study, we evaluated the relative contribution of these factors in patients with metabolic syndrome.
We conducted a cross-sectional study of 67 men and 46 postmenopausal women with metabolic syndrome; metabolic syndrome was defined as
having three or more metabolic syndrome risk factors. BMD, body fat mass, and lean body mass were evaluated. We also examined the levels 
of high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), adiponectin, vitamin E, and C in serum. Log-transformed hs-CRP levels were
significantly higher in lumbar spine osteoporotic subjects than in normal subjects for women but not for men. There was no significant difference
between the normal group and the osteoporotic group in other inflammatory markers. Stepwise regression analyses for BMD of the lumbar spine
showed that lean body mass and vitamin E were significant determinants in men. Lean body mass and log-transformed hs-CRP were significant 
determinants in women Analysis for BMD of the femoral neck showed that lean body mass was a significant determinant for both men and women.
There was no significant factor among the inflammatory markers or antioxidant vitamins affecting the femoral neck BMD for either gender. In
conclusion, while hs-CRP is an independent predictor of the BMD of the lumbar spine in women, vitamin E showed profound effects on BMD
in men but not women with metabolic syndrome. 
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Introduction9)
Metabolic syndrome is associated with various health risk 
factors, such as hypertension, abnormal blood sugar and lipid 
profiles, and abdominal obesity. In the United States, approximately 
25% of the total population has been reported to have metabolic 
syndrome, 45% of that in people age 50 or older [1-3]. According 
to the Korean National Health and Nutrition Examination Survey 
conducted in 2005, 32.9% of Korean men and 31.8% of Korean 
women have metabolic syndrome [4]. Patients with metabolic 
syndrome tend to have a higher risk of developing diabetes 
mellitus and cardiovascular diseases (CVD) [5]. Therefore, 
according to the National Cholesterol Education Program Adult 
Treatment Panel III (NECP-ATP III), the active prevention of 
metabolic syndrome is recommended to prevent or delay the 
onset of CVD [3]. 
The main pathogenic mechanism of metabolic syndrome relies 
on insulin resistance, low-level inflammation, and oxidative stress 
[6]. In the category of inflammation, it has been shown that high 
sensitive C-reactive protein (hs-CRP), IL-6, and adiponectin are 
independent factors for CVD [7]. In metabolic syndrome, 
excessive fat accumulation induces free radical generation and 
fosters oxidative damage in tissue [8]. In addition, low lycopene, 
β-carotene [9], vitamin C, and α-tocopherole consumption rates 
enhance systemic oxidative stress in metabolic syndrome patients 
[10]. This may explain the correlation between the complications 
associated with metabolic syndrome, oxidative stress, and infla-
mmation. 
Recently, risk factors associated with metabolic syndrome, 
such as hypertriglyceridemia, low high-density lipoprotein 
(HDL), cholesterolemia, and abdominal obesity, were shown to 
be associated with decreased bone mineral density (BMD) 
[11-12]. In one study, BMD was significantly lower in male patients 
with metabolic syndrome compared to a control group [13]. In 
a study of the Korean population, the odds ratio of the prevalence 
of metabolic syndrome was 3.07 times higher in male patients 
with osteodyspenia [14], and the BMD of the femoral neck was 
significantly lower in patients with metabolic syndrome compared 
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to healthy people [15]. Although this mechanism has not been 
clarified, the origin of adipose cells and osteoblasts from the same 
mesenchymal stem cells has been postulated as the key factor 
contributing to the correlation between metabolic syndrome and 
BMD [16]. In addition, peroxisome proliferator-activated receptor-
γ (PPAR-γ) and many types of cytokines have been reported 
to regulate the differentiation and proliferation of these two cells 
[17-18]. Adiponectin, which is involved in bone formation and 
inflammation, functions in maintaining energy homeostasis, 
anti-inflammatory effects, and anti-atherogenic effects. It also 
protects body fat during osteolysis [19], and inhibits bone 
formation by interfering with the stimulation of the receptor 
activator of nuclear factor-kappaB ligand (RANKL) and the 
formation of Osteoprotegerin (OPG) [20]. An acute inflammatory 
molecule, C-reactive protein (CRP), which is formed by IL-6 
and tumor necrosis factor-α (TNF-α) in the liver, is a sensitive 
marker that predicts the risk of developing CVD [21-23]. In 
association with bone metabolism, hs-CRP reportedly has a 
negative correlation with BMD [24] but shows a positive 
correlation with bone turnover rate [25]. A recent study has 
shown that there is a positive correlation between hs-CRP and 
biochemical bone markers, which implies a higher possibility of 
an asymptomatic inflammatory response to mediate the increased 
bone turnover [26].
To date, a limited number of studies have been conducted to 
examine the relationship between BMD, various types of inflamma-
tion biomarkers, and antioxidant vitamins in patients with 
metabolic syndrome. In addition, there are few studies of gender- 
specific principal risk factors that affect bone formation. Therefore, 
we examined the gender-specific relationship of inflammatory 
markers, antioxidants, and BMD in patients with metabolic syndrome.
Subjects and Methods
Subjects
The subjects of this study were a subset of all patients who 
visited the Health Promotion Center for a regular medical 
check-up at the University Hospital in Kyounggi province 
between 21 September 2009 and 5 February 2010. Clinical 
diagnosis of metabolic syndrome was based on the criteria 
outlined in a joint interim statement from the International 
Diabetes Federation and the American Heart Association/ 
National Heart, Lung, and Blood Institute [27]. Metabolic 
syndrome was diagnosed in cases with: serum triglyceride > 150 
mg/dl, serum HDL-cholesterol < 40 mg/dl in men and < 50 mg/dl 
in women, fasting blood sugar > 100 mg/dl or taking anti-diabetic 
drugs, systolic blood pressure > 130 mmHg or diastolic pressure 
> 85 mmHg or taking anti-hypertensive drugs and an abdominal 
circumference > 90 cm in men and > 80 cm in women. Patients 
who exhibited more than three of the five factors associated with 
metabolic syndrome and whose BMD was measured were 
selected as subjects for the study. Patients with diabetes 
complications, cardiovascular or cerebrovascular disease, or 
chronic liver disease were excluded. The study was approved 
by the Institutional Review Board (IRB) of the Bundang Seoul 
National University Hospital. A total of 67 men and 46 
postmenopausal women were enrolled in the study and submitted 
written informed consent.
Physical examination
The height and weight of the subjects were measured using 
an automatic recorder, DS-102 (Jenix Co, Korea). Body mass 
index (BMI) was calculated as weight divided by height squared. 
Lean body mass and body fat percentage were measured with 
a bioelectrical impedance analysis, X-SCAN Plus II (Jawon 
medical, Korea); subjects wore minimal clothing, no shoes, socks, 
or metal substances.
Abdominal circumference was measured at the mid-point 
between the iliac crest and the inferior border of the ribs in a 
standing position. Blood pressure was measured using an 
automatic blood pressure monitor, Sysmex XE-2100(Sysmex, 
Japan) from a sitting position.
Measurement of BMD
BMD was assessed with a Dual Energy X-ray Absorptiometry, 
measured at the lumbar spine from L1 to L4. BMD of the femoral 
neck of the femur was measured with Lunar Prodigy (General 
Electric system, USA). BMD was expressed in g/cm
2. At each 
site, patients with a t-score ≧-1 were put into the normal group, 
and those with a t-score < -1 were put into the osteopenia group, 
as defined by the World Health Organization [28].
Biochemical assay
Venous blood was collected from test subjects after an 
overnight fast, and blood was centrifuged at 3,000rpm for 15 
minutes. The isolated serum was used to analyze glucose, 
triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol, 
and gamma glutamyl transferase using BS-220 (Mindray, China). 
Hs-CRP was analyzed using a Hitachi 7600-110 (Hitachi, Japan), 
based on latex agglutination immunoassay. Serum Adiponectin 
was measured using an Enzyme Immuno Assay (EIA) with an 
Adiponectin ELISA kit (Adipogen, Korea). Serum IL-6 
concentrations were also measured using an EIA with an IL-6 
kit (Bender Medsystems, Austria). A vitamin E assay was 
performed based on the Bieri methods [29], for which High 
Performance Liquid Chromatography (HPLC) was used. In the 
serum two internal standards and n-hexane were extracted twice 
for a total volume of 400 μl. Centrifugation was done again at 
1,500 rpm for ten minutes, and the supernatant was taken. The 
isolated supernatant was filtered through a 0.45 μm syringe filter, 
dried with nitrogen gas, and then dissolved with 50 μl methanol. 152 Cytokines and BMD in metabolic syndrome patients
Variables Men
(n = 67)
Women
(n = 46)
Total
(n = 113) P-value
Age (yrs) 55.04 ± 7.54
1) 54.26 ± 7.57 54.73 ± 7.53 0.589
Height (cm) 171.99 ± 6.74  157.04 ± 4.53  165.90 ± 9.45  < 0.001
Weight (kg) 78.67 ± 10.20  64.34 ± 8.81  72.83 ± 11.94  < 0.001
BMI (kg/m
2)
2) 26.54 ± 2.50 26.13 ± 3.70 26.37 ± 3.04  0.484
LDL-C (mg/dl)
3) 110.04 ± 27.48 120.83 ± 32.79 114.43 ± 30.09  0.061
GGT (IU/L)
4) 53.76 ± 33.97 42.33 ± 36.44 49.11 ± 35.29 0.091
Cholesterol (mg/dl) 197.90 ± 34.17  215.85 ± 36.86 205.20 ± 36.23  0.009
serum Vitamin E 
(μmol/l)
22.10 ± 6.95 26.26 ± 10.75 23.79 ± 8.88 0.014
serum Vitamin C 
(mg/l)
6.83 ± 3.47 8.77 ± 4.13 7.62 ± 3.86 0.008
hs-CRP (mg/l)
5) 1.93 ± 2.35 2.22 ± 2.71 2.05 ± 2.50 0.541
Adiponectin (μg/ml) 8.12 ± 2.64 10.63 ± 2.96 9.14 ± 3.03 < 0.001
IL-6 (pg/ml)
6) 1.07 ± 2.16 1.02 ± 1.55 1.05 ± 1.93  0.964
Lean body mass (kg) 58.36 ± 7.55  42.31 ± 3.85  51.83 ± 10.11  < 0.001
Fat mass (kg) 20.30 ± 3.99 22.03 ± 5.51 21.01 ± 4.72 0.991
Percent body fat (%) 25.73 ± 3.11  33.82 ± 3.91  29.02 ± 5.27  < 0.001
Metabolic syndrome Indicators
Central obesity (%) 50 (74.6) 44 (95.7) 94 (83.2) 0.003
High Triglyceride (%) 39 (58.2) 27 (58.7) 66 (58.4) 0.959
High FPG (%)
7) 40 (59.7) 15 (32.6) 55 (48.7) 0.005
Low HDL-C (%)
8) 40 (59.7) 20 (43.5) 60 (53.1) 0.091
High Blood 
pressure (%)
43 (64.2) 26 (56.5) 69 (61.1) 0.414
1) Mean ± SD
2) BMI:  body  mass  index
3) L D L - C :  l o w - d e n s it y  li p o p r o t e i n  c h o le s t e r o l
4) GGT:  gamma-glutamyl  transferase
5) hs-CRP:  high-sensitivity  C-reactive  protein
6) IL-6:  interleukin-6
7) FPG:  fasting  plasma  glucose
8) HDL-C:  high-density  lipoprotein  cholesterol
Table 1. Characteristics of study subjects
Variables Men
(n = 67)
Women
(n = 46)
Total
(n = 113) P
BMD Lumbar spine (g/cm
2)
3) 1.23 ± 0.18
1) 1.11 ± 0.14 1.18 ± 0.17  0.000
BMD Lumbar spine (t-score) 0.42 ± 1.49  0.00 ± 1.14  0.25 ± 1.37 0.115
BMD Femoral neck (g/cm
2) 0.95 ± 0.12 0.88 ± 0.10 0.92 ± 0.12 0.001
BMD Femoral neck (t-score) -0.02 ± 0.91  -0.21 ± 0.84 -0.10 ± 0.88 0.279
Lumbar spine t-score (%)
Normal 54 (80.6)
2) 37 (80.4) 91 (80.5)
0.983
Osteopenia + Osteoporosis 13 (19.4) 9 (19.6) 22 (19.5)
Femoral neck t-score (%)
Normal 56 (83.6) 38 (82.6) 94 (83.2)
0.892
Osteopenia + Osteoporosis 11 (16.4) 8 (17.4) 19 (16.8)
1) Mean ± SD
2) N  (%)
3) BMD:  bone  mineral  density
Table 2. Bone mineral density status
The column was analyzed with Nova-Pak C18 (Waters, USA), 
and the mobile phase was analyzed with methanol/H2O 
(95%/5%). At a UV wavelength of 292 nm, a quantitative 
analysis was performed at a flow rate of 1.5 ml/min using HPLC 
(Shimadzu, Japan). An analysis of serum vitamin C was 
comissioned to Samkwang Medical Labora fories and was 
performed with HPLC [30]. For this, 200 μl of serum was mixed 
with 5% metaphosphoric acid and centrifuged to remove the 
precipitated proteins. A 20 μl aliquot of the centrifuged extract 
was injected into HPLC.
Statistical analysis
All of the statistical analyses were performed using Statistical 
Package for Social Science 12.0, and statistical significance was 
considered to be P < 0.05. Mean differences in antioxidant 
vitamins and other continuous variables between men and women 
were analyzed with a t-test. The gender difference distribution 
of metabolic syndrome indicators and BMD were determined 
with a chi-square test. To identify the correlation between 
inflammation biomarkers, BMD, and antioxidant vitamins, partial 
correlation coefficients were obtained after an age and weight 
adjustment. An evaluation of normality was performed with a 
Shapiro-Wilk test, and logarithmic transformations were performed 
for serum hs-CRP, adiponectin, and IL-6 concentrations due to 
a positively skewed distribution. In both male and female 
patients, after adjustments for age and BMI, the means and 95% 
confidence intervals of log-transformed hs-CRP concentrations 
were compared by analysis of covariance (ANCOVA) among the 
subjects’ BMD status (normal vs. osteopenia + osteoporosis).
To identify the factors affecting BMD, a multiple regression 
analysis was performed after adjustment for age. Body compositions 
(percentage of body fat and lean body mass), antioxidant vitamins 
(vitamin E and C), and inflammatory markers (hs-CRP, IL-6, 
adiponectin) were examined using a stepwise analysis, retaining 
only those variables that were statistically significant. 
Results
General characteristics and biochemical assessment
The baseline characteristics of the subjects are summarized in 
Table 1. There was no significant difference in the distribution 
of triglycerides, blood pressure, or HDL-cholesterol between men 
and women. There was no significant difference in the level of 
serum hs-CRP or IL-6 between men and women. The mean value 
of adiponectin was significantly higher in women than in men 
(P < 0.001). Antioxidant vitamin levels, including vitamin E (P
<0 . 0 5 )  a n d  C  ( P < 0.01), were also higher in women than in 
men. Lean body mass was significantly higher in men than in 
women (P< 0.001), and percentage of body fat was significantly 
higher in women than in men (P < 0.001).
BMD analysis
The results for BMD are presented in Table 2. The BMD of 
the lumbar spine (P < 0.001) and femoral neck (P < 0.001) was 
higher in men than in women. 
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BMD
1)
log hs-CRP
2) log adiponectin log IL-6
3) Vitamin C Vitamin E
Correlation 
coefficient P Correlation 
coefficient P Correlation 
coefficient P Correlation 
coefficient P Correlation 
coefficient P
Lumbar spine (g/cm
2) Men -0.070 0.288 -0.55 0.330 0.170 0.085 0.021 0.432 0.218 0.038
Women -0.320 0.015 0.109 0.235 0.123 0.208 -0.020 0.887 -0.184 0.089
Lumbar spine (t-score) Men -0.068 0.293 -0.057 0.324 0.165 0.091 0.021 0.434 0.214 0.041
Women -0.319 0.015 0.098 0.258 0.107 0.240 -0.017 0.901 -0.192 0.080
Femoral neck (g/cm
2) Men 0.002 0.494 0.054 0.331 -0.073 0.279 -0.036 0.387 0.014 0.455
Women -0.072 0.318 -0.195 0.097 0.184 0.110 -0.106 0.220 -0.213 0.059
Femoral neck (t-score) Men 0.000 0.499 -0.076 0.271 0.051 0.341 -0.030 0.404 0.015 0.453
Women -0.060 0.345 -0.207 0.084 0.166 0.135 -0.101 0.232 -0.229 0.046
1) BMD:  bone  mineral  density
2) hs-CRP:  high-sensitivity  C-reactive  protein
3) IL-6:  interleukin-6
Table 3. Correlation of bone mineral density with inflammatory markers and antioxidant vitamins
Male
a. Lumbar spine b. Femoral neck
Fig. 1. Serum high-sensitivity C-reactive protein (hs-CRP) concentrations among normal and osteopenic male subjects. Serum hs-CRP concentrations were given 
as estimated mean ± 95% confidence intervals. 
Female
a. Lumbar spine b. Femoral neck
Fig. 2. Serum high-sensitivity C-reactive protein (hs-CRP) concentrations among normal and osteopenic female subjects. Serum hs-CRP concentrations were given 
as estimated mean ± 95% confidence intervals. 
subjects were classified into two groups: the normal BMD group 
(t-score ≧-1) and the osteopenia group (t-score < -1). Based on 
the BMD of the lumbar spine, 54 male subjects (80.6%) were 
included in the normal BMD group, and 13 male subjects (19.4%) 154 Cytokines and BMD in metabolic syndrome patients
Men Women
β P F (P) β P F (P)
BMD Lumbar spine
1)
7.022 (0.000)
BMD Lumbar spine
8.863 (0.000)
Lean body mass 0.460 0.000 Lean body mass 0.307 0.026
Vitamin E 0.222 0.053 log hs-CRP
2) -0.358 0.008
R
2 =0 . 2 5 R
2 =0 . 3 9
BMD Femoral neck
6.934 (0.002)
BMD Femoral neck
8.470 (0.000)
Lean body mass 0.430 0.001 Lean body mass 0.299 0.054
% Body fat -0.231 0.112
R
2 =0 . 1 8 R
2 =0 . 3 8
1) BMD:  bone  mineral  density
2) hs-CRP:  high-sensitivity  C-reactive  protein
Table 4. Multiple regression analysis for gender-specific bone mineral density
were included in the osteopenia group. When considering the 
BMD of the femoral neck, these numbers were 56 (83.6%) and 
11 male subjects (16.4%), respectively. Based on the BMD of 
the lumbar spine, there were 37 female subjects (80.4%) in the 
normal group and 9 female subjects (19.6%) in the osteopenia 
group. When considering the BMD of the femoral neck, these numbers 
were 38 (82.6%) and 8 female subjects (17.4%), respectively.
Correlation between inflammatory markers, antioxidant vitamins, 
and BMD
The correlations between BMD and hs-CRP, adiponectin, IL-6, 
and antioxidant vitamins (vitamins E and C) are presented in 
Table 3. An analysis following adjustment for age and weight 
revealed that male subjects had a significantly positive correlation 
between BMD and serum vitamin E (r = 0.218, P = 0.038) and 
between the t-score of the lumbar spine and serum vitamin E 
(r = 0.214,  P = 0.041). In women, there was a significantly 
negative correlation between log-transformed hs-CRP and the 
BMD of the lumbar spine (r = -0.320, P = 0.015) and between 
log-transformed hs-CRP and the t-score of the lumbar spine (r
= -0.319,  P = 0.015). There was a significantly negative 
correlation between the t-score of the femoral neck and serum 
vitamin E in women (r = -0.229, P =0 . 0 4 6 ) .
Comparison of hs-CRP concentrations according to BMD status
We compared log-transformed serum hs-CRP concentrations 
with BMD status. There was no significant difference in hs-CRP 
concentrations related to BMD status in men (Fig. 1). In women, 
however, hs-CRP levels were significantly higher in the lumbar 
spine osteoporotic group than in the normal group (F = 4.447, 
P = 0.037) (Fig. 2).
Analysis of factors related to BMD
Table 4 shows the effects of factors associated with BMD in 
patients with metabolic syndrome. Following stepwise regression 
analyses for BMD of lumbar spine, lean body mass, and vitamin 
E were independent variables in men, and lean body mass and 
log-transformed hs-CRP were significant variables in women. 
Lean body mass was a significant variables in men, and lean 
body mass and percentage of body fat were significant variables 
in BMD of women in femoral neck.
Discussion
Many studies have reported a close link between metabolic 
syndrome and CVD [1-3]. Also, recent studies have shown that 
there is a correlation between metabolic syndrome and BMD 
[13-15]. Understanding the main factors that affect BMD in 
patients with metabolic syndrome would contribute to identifying 
the common risk factors that link CVD and osteoporosis. Gender 
has been identified as a risk factor associated with CVD [31], 
so we extrapolated that there might be a gender difference 
affecting bone formation in metabolic syndrome patients. Results 
of this study show that hs-CRP level was a negatively associated 
significant variable predicting lumbar spine BMD in women. 
There was no significant relationship between BMD and hs-CRP 
level in men, and IL-6 and adiponectin levels were not associated 
with BMD in either men or women. Pro-inflammatory cytokines, 
such as interleukin IL-6 and CRP, have been shown to regulate 
bone metabolism in healthy women. According to Bae et al. [25], 
as hs-CRP serum concentration levels increase BMD decreases 
and bone turnover rate increases. In another population-based 
study, women with osteopenia had higher serum hs-CRP levels 
than those with normal BMD. Therefore, it is suggested that 
subclinical systemic inflammation may be associated with bone 
turnover rate and bone mass in healthy women [32]. The 
relationship between pro-inflammatory cytokines and BMD in 
men is inconclusive. In men with metabolic syndrome, a trend 
toward reduced BMD with higher CRP levels was identified [33]. 
According to an epidemiologic study, increased systemic infla-
mmation was a risk factor for lower BMD among premenopausal 
women, but not for men [34]. IL-6 has been known to promote 
osteoclast differentiation and is associated with femoral bone loss 
in healthy postmenopausal women [35]. The relationship between Yesong Lee et al. 155
serum adiponectin levels and BMD is controversial [36-37]. In 
this study, we found that change in serum hs-CRP levels might 
be a more sensitive marker for predicting lumbar spine BMD 
change than other inflammatory markers, especially in women 
patients. The association of hs-CRP levels and BMD at the 
lumbar spine was higher than that at the femoral neck. The reason 
for this is not entirely clear; it may be that higher surface- 
to-volume ratio in the spine than in the femoral neck causes more 
metabolic activity. Because there not enough definite results 
about inflammatory markers and the mechanisms associated with 
BMD, further studies should be conducted. 
For femoral neck BMD, percentage of body fat was a significant 
variable in women. Although the mechanism underlying this 
relationship is not clear, this finding suggests that body fat may 
have harmful effects on bone. It has been widely understood that 
visceral fat is not only used for the storage and mobilization 
of lipids but is also a remarkable endocrine organ that releases 
adipokines, which play an important role in bone formation and 
the pathogenesis of osteoporosis [38-39]. It is feasible that 
low-grade inflammation derived from visceral adiposity may be 
associated with bone loss in postmenopausal patients with 
metabolic syndrome.
This study revealed an opposite relationship between vitamin 
E levels and BMD in men and women. In a multiple linear 
regression analysis, vitamin E was a predictor for BMD in men 
only, which suggests that vitamin E may exert a positive influence 
on bone mass in patients with metabolic syndrome. Recent 
evidence suggests that vitamin E, in addition to its antioxidant 
properties, has a protective effect against bone deformation from 
inflammatory cytokine synthesis. Vitamin E consumption has 
been associated with a lowered risk of coronary heart disease 
and reduced low-density lipoprotein oxidation [9]. Palmieri et 
al. [10] reported that serum vitamin E concentration was lower 
in patients with metabolic syndrome than in controls, showing 
unbalanced serum redox with decreased lipid antioxidant capacity. 
However, the positive association seen between increased 
hs-CRP levels and increased vitamin E levels in women may 
be due the pro-oxidant effects of vitamin E [40-41]. Further 
research is required to confirm the gender difference in the 
potential of vitamin E and to understand bone and oxidative stress 
in patients with metabolic syndrome.
There were several limitations to this study. First, the experimental 
group consisted of a small, heterogeneous sample of metabolic 
syndrome patients who visited a health promotion center, which 
may have resulted in a biased selection. We would like to confirm 
our findings in a larger number of subjects. Second, this was 
cross-sectional study that did not clarify whether there was a 
causal relationship between inflammatory markers, antioxidant 
vitamins, and BMD. Further studies would be necessary to clarify 
if there is a causal relationship among these factors. We have 
shown that incremental serum hs-CRP concentrations are 
associated with lower BMD, and that hs-CRP is an independent 
factor of BMD in women but not men with metabolic syndrome. 
These finding suggest that reducing subclinical systematic 
inflammation may be an important factor in conserving bone 
mass, especially in women with metabolic syndrome. 
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